Embed Size (px)
Citation preview
InnVentis
From Big DATA to
Precision Medicine ?Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease Committee on a Framework for Development a New Taxonomy of Disease
Preparing for Precision Medicine World Economic Forum November 2012
By 2020, four out of every five drugs launched will be Precision Medicine drugs
The precision medicine revolution: Targeted treatment zeros in on disease; GE Look ahead 2013
Precision Medicine © Dr. Thomas Wilckens, InnVentis
InnVentis
Precision Medicine - Paradigm Shift
Symptom-based Cohort-based Algorithm-based
Yesterday
Intuition Medicine
Today
Evidence-based Medicine
Tomorrow
Precision Medicine
DATA
ACTI
ON
S
Application of rules, algorithms and reference databases enables ACTIONABLE clinical decision support & PRECISE/EFFICIENT care
Reference Databases (Rules &
Algorithms)
Personal Molecular
Profiles(PMP, multi-omics)
Molecular Imaging
Non-molecular content (waveforms)
Precision Medicine
(prevention, diagnosis, treatment)
MobileInformation
CommunicationTechnologies
Big DataAnalytics
Precision Medicine © Dr. Thomas Wilckens, InnVentis
InnVentisFrom Big DATA to PRECISION MEDICINE:We need vertically integrared flagship projects
…Although grand in overall scope, precision medicine can succeed iteratively and likely can move forward only through pilot studies—some that will establish STANDARDS and
best practices and some that will be SCALABLE, illuminating routes toward larger and broader efforts..
K. Yamamoto, SCIENCE Translational Medicine August 2015:
InnVentisDisrupting Biopharmaceutical R&D:The pressing need to improve R&D of Drug and Diagnostics
Broken drug discovery paradigm,not sustainable costs in R&D
Data overflow (*omics deluge)
No standards and SOPs: Garbage in – Garbage out
The Cost Of Creating A New Drug (up to) $5 Billion US-$, Pushing Big Pharma To Change 11/2013
"One of the biggest challenges in medicine and science today is how to interpret the vast amount of biological data we are generating... To make these data interpretable and clinically actionable will require new computational tools.”
Craig Venter 08/2014
4
InnVentis
5
The SNYDEROME:Multi-omics, longitudinal mapping of one single person
20 different snapshots in 14-months 40,000 molecular parameters per blood
sample 50 Terabytes of data $2,000 each blood sample,
only reagents, not counting costs for analysis, staff, storage etc.
40 co-authors
Costs: 10M US$
Mike Snyder, CELL, Volume 148, Issue 6, p1293–1307, 16 March 2012 Precision Medicine © Dr. Thomas Wilckens, InnVentis
InnVentis
InnVentis Ltd.Inflammation is a major driver of virtually every significant chronic human disease…
InnVentis develops products & services to enable the development of new drugs as well as precise diagnostics & treatment decisions
Value creation from multi-omics & machine learning
InnVentisInflammation, a key driver of major chronic diseases
InnVentis 1st focus arthritis:
• Most Common Cause of Disability
• Affects all ages
• Cost in the U.S. $128 billion/year
Rheumatoid arthritis (RA)• 1% of the worldwide population
• Major impact on productivity
• U.S. $40 billion/year in the US
• Poorly diagnosed
• “Trial & Error” treatment decision
InnVentis
Genome25.000 genes
Proteome1 million
Metabolome > 6000 SM
Microbiom1-3 % of
body mass
Existing knowledge ?
Big DATA
Pattern Discovery
Reference Database Machine learning
Algorithms
PersonalMolecular
Profile
Drug Molecular
Profile
Convergence of diagnostics with Big-Data & AI:Multi-omics create Personal Molecular Profile, PMP and Drug Molecular Profile
InnVentis creates & integrates standardized data in a proprietary analytics architecture.
Sample collection KIT
InnVentis
105
data points
each sample
Treatment
RemissionHealthy
1 2 3 1514
Omics-derived PMP and DMP deciphered from few allow stratification of many into specific subgroups
approximately 15 measurements in 18months
InnVentis ‘ new paradigm: Intra-individual longitudinal multi-omics analysis replaces cohort based medicine
Disease onset
InnVentis
Precision Medicine © Dr. Thomas Wilckens, InnVentis
Disease Drug 1
Molecular profiling of drug actions:Identifying responders with PMP and DMP
Drug 2 Drug 3 Remission
InnVentis
Team & board comprises 350+ years industry experience:Success is about people
Leadership in ICT/Big DATA, diagnostics and biopharmaceutical R&D
invested 2000+ days in „sweat money“ & proprietary assets…
InnVentis
Precision Medicine & Big DATA
InnVentis enabling
PRECISION MEDICINE
Disclaimer:This presentation is for educational purposes only. No copyright violations are intended.Distribution, also in part, for commercial purpose is illigal
?
Precision Medicine © Dr. Thomas Wilckens, InnVentis
InnVentisGarbage in – Garbage out?Preclincial data
An analysis of past studies indicates that the cumulative (total) prevalence of irreproducible preclinical research exceeds 50%, resulting in approximately US$28,000,000,000 (US$28B)/year spent on preclinical research that is not reproducible—in the United States alone.
The Economics of Reproducibility in Preclinical Research, PLOS 2015
InnVentis
14
Nature Reviews Drug Discovery | 21 September 2015
Garbage in – Garbage out?Drug discovery
Tackling reproducibility in academic preclinical drug discovery
The reproducibility of biomedical research on novel drug targets has become suspect. Here, we highlight how drug discovery centres embedded in academic institutions, but with a translational imperative, can help address this reproducibility crisis.
InnVentisGarbage in – Garbage out?Biomarker studies
Most biomarker discovery still takes place in government-funded university laboratories that are ill equipped to undertake the myriad procedures required for stringent biomarker profiling on the scale required to achieve the evidence needed to attract larger investment in clinical trials.
National Biomarker Development Alliance 9/2014
InnVentisGarbage in – garbage out?Do Watson etc. create insight & value?
Nature 03 April 2013If a job is worth doing, it is worth doing twiceResearchers and funding agencies need to put a premium on ensuring that results are reproducible
How much existing „knowledge“ can be used, how?
InnVentis
Standards and SOPs on the horizon to secure value today?The case for vertically integrated lean, fast pilot projects
Launch of a Transformative Health Care Initiative: The National Biomarker Development Alliance (NBDA) 1/2014
Problems with scientific researchHow science goes wrongScientific research has changed the world. Now it needs to change itself 10/2013
A sea of standards for omics data: sink or swim?JD Tenenbaum et. al. Am Med Inform Assoc, 09/2013
SOPs=
Value
Precision Medicine © Dr. Thomas Wilckens, InnVentis
Establishing data bases and algorithms requires highest comparability, validity & reliability
InnVentisSelected questions:
• Are current methods for sample collection and biobanking aligned with hypersensitive *omics methods
• How much can you trust the sample handling procedures at academic or CRO sites?
• How can we validate machine/deep learning algorithms
• Others …….
